Restatement of Previously Issued Financial Statements - Schedule of Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Consolidated Statements of Operations
Revenues	$ 34,757	$ 33,121
Cost of revenues	27,369	26,135
Gross margin	7,388	6,986
Operating expenses:
Selling, general and administrative	22,732	16,948
Research and development	4,166	1,144
Restructuring charges	1,698	860
Transaction expenses	0	1,103
Goodwill impairment	0	85,000
Operating loss	(21,208)	(98,069)
Net increase in fair value of derivatives	33,336	23,807
Interest expense	5,116	6,385
Other income	(276)	(455)
Loss before taxes	(61,961)	(127,806)
Income tax benefit	25	(14)
Net loss	$ (61,986)	(127,792)
As reported
Consolidated Statements of Operations
Revenues		33,121
Cost of revenues		26,135
Gross margin		6,986
Operating expenses:
Selling, general and administrative		16,948
Research and development		1,144
Restructuring charges		860
Transaction expenses		1,103
Goodwill impairment		85,000
Operating loss		(98,069)
Net increase in fair value of derivatives		23,992
Interest expense		3,555
Other income		(455)
Loss before taxes		(125,161)
Income tax benefit		(14)
Net loss		(125,147)
Adjustment
Consolidated Statements of Operations
Revenues		0
Cost of revenues		0
Gross margin		0
Operating expenses:
Selling, general and administrative		0
Research and development		0
Restructuring charges		0
Transaction expenses		0
Goodwill impairment		0
Operating loss		0
Net increase in fair value of derivatives		(185)
Interest expense		2,830
Other income		0
Loss before taxes		(2,645)
Income tax benefit		0
Net loss		$ (2,645)